Affinity DataIC50: 0.200nMAssay Description:The in vitro antiviral activity of the compounds was determined using a cell-based antiviral assay. In this assay, the cytopathic effect (CPE) in Mad...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The in vitro antiviral activity of the compounds was determined using a cell-based antiviral assay. In this assay, the cytopathic effect (CPE) in Mad...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The in vitro antiviral activity of the compounds was determined using a cell-based antiviral assay. In this assay, the cytopathic effect (CPE) in Mad...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The in vitro antiviral activity of the compounds was determined using a cell-based antiviral assay. In this assay, the cytopathic effect (CPE) in Mad...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The in vitro antiviral activity of the compounds was determined using a cell-based antiviral assay. In this assay, the cytopathic effect (CPE) in Mad...More data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:The in vitro antiviral activity of the compounds was determined using a cell-based antiviral assay. In this assay, the cytopathic effect (CPE) in Mad...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:The in vitro antiviral activity of the compounds was determined using a cell-based antiviral assay. In this assay, the cytopathic effect (CPE) in Mad...More data for this Ligand-Target Pair
Affinity DataIC50: 26nMAssay Description:The in vitro antiviral activity of the compounds was determined using a cell-based antiviral assay. In this assay, the cytopathic effect (CPE) in Mad...More data for this Ligand-Target Pair
Affinity DataIC50: 130nMAssay Description:The in vitro antiviral activity of the compounds was determined using a cell-based antiviral assay. In this assay, the cytopathic effect (CPE) in Mad...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 740nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 802nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 821nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 825nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 830nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 927nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 944nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 973nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 998nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.00E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.00E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.01E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.02E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.02E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.03E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.04E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.06E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.06E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.07E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.13E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.13E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.14E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.14E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.14E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.17E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.17E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.19E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.20E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.23E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.26E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.27E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.29E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.31E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.31E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.35E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.35E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.37E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.41E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.43E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.43E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.44E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair